Target Name: TOGARAM1
NCBI ID: G23116
Other Name(s): crescerin-1 | TOG array regulator of axonemal microtubules 1 | crescerin | TOGARAM1 variant 2 | TOG array regulator of axonemal microtubules protein 1 (isoform 1) | protein FAM179B | TOG array regulator of axonemal microtubules protein 1 (isoform 2) | TOGARAM1 variant 1 | Crescerin | TOG array regulator of axonemal microtubules 1, transcript variant 2 | JBTS37 | KIAA0423 | TGRM1_HUMAN | TOG array regulator of axonemal microtubules 1, transcript variant 1 | TOG array regulator of axonemal microtubules protein 1 | FAM179B | Crescerin-1 | Family with sequence similarity 179 member B | family with sequence similarity 179 member B

TogARAM1: A Promising Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Introduction

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are progressive disorders that affect the brain and nervous system. These conditions are characterized by the progressive loss of brain cells, leading to a range of symptoms, including cognitive decline, motor dysfunction, and behavioral changes. Current treatments for these diseases are limited and often have significant side effects. Therefore, there is a need for new and effective therapies that can slow the progression of these conditions and provide effective relief from symptoms.

Togaram1 (also known as resorcetin-1) is a naturally occurring compound that has been shown to have anti-inflammatory properties and may be a promising drug target and biomarker for the treatment of inflammatory neurodegenerative diseases. In this article, we will discuss the properties of Togaram1, its potential as a drug target, and its potential as a biomarker for the diagnosis and progression of inflammatory neurodegenerative diseases.

Properties of Togaram1

Togaram1 is a small molecule that is derived from the resorcetin family of compounds. It is a white crystalline powder with a wide range of biological activities. Togaram1 has been shown to have anti-inflammatory properties by inhibiting the production of inflammatory cytokines, such as TNF-alpha, IL-1, and IL-6, and by reducing the expression of pro-inflammatory genes, such as NF-kappa-B and AP-1.

In addition to its anti-inflammatory properties, Togaram1 has also been shown to have pro-resolving effects, which may be useful for the treatment of neurodegenerative diseases. Pro-resolving effects are a type of cellular response that helps to repair damaged tissue and reduce inflammation. Togaram1 has been shown to promote the production of brain-derived neurotrophic factor (BDNF) and to protect against neurotoxicity in animal models of neurodegenerative diseases.

Potential as a drug target

Togaram1's anti-inflammatory and pro-resolving effects make it an attractive drug target for the treatment of inflammatory neurodegenerative diseases. Several studies have shown that Togaram1 can be effective in animal models of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In particular, Togaram1 has been shown to be effective in the treatment of Alzheimer's disease, which is a progressive neurodegenerative disorder that is characterized by the progressive loss of brain cells. Studies have shown that Togaram1 can improve memory and cognitive function in animal models of Alzheimer's disease and can protect against neurotoxicity in these models.

Togaram1 may also be an effective drug target for the treatment of other inflammatory neurodegenerative diseases, such as Parkinson's disease and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and the progressive degeneration of neural circuits. Togaram1 has been shown to be effective in animal models of Parkinson's disease, as well as in the treatment of neurotoxicity in these conditions.

Potential as a biomarker

Togaram1 may also be a useful biomarker for the diagnosis and progression of inflammatory neurodegenerative diseases. The development of new biomarkers for neurodegenerative diseases is an important area of 鈥嬧?媟esearch, as these conditions are often diagnosed based on the symptoms and course of the disease, which can be difficult to follow and can vary significantly from one patient to

Protein Name: TOG Array Regulator Of Axonemal Microtubules 1

Functions: Involved in ciliogenesis (PubMed:32453716). It is required for appropriate acetylation and polyglutamylation of ciliary microtubules, and regulation of cilium length (PubMed:32453716). Interacts with microtubules and promotes microtubule polymerization via its HEAT repeat domains, especially those in TOG region 2 and 4 (By similarity)

More Common Targets

TOGARAM2 | Toll-Like Receptor | TOLLIP | TOLLIP-DT | Tolloid-like protein | TOM complex | TOM1 | TOM1L1 | TOM1L2 | TOMM20 | TOMM20L | TOMM20P2 | TOMM22 | TOMM34 | TOMM40 | TOMM40L | TOMM40P2 | TOMM5 | TOMM6 | TOMM7 | TOMM70 | Tomoregulin | TONSL | TONSL-AS1 | TOP1 | TOP1MT | TOP1P1 | TOP1P2 | TOP2A | TOP2B | TOP3A | TOP3B | TOP3BP1 | TOPAZ1 | TOPBP1 | TOPORS | TOR1A | TOR1AIP1 | TOR1AIP2 | TOR1B | TOR2A | TOR3A | TOR4A | TOX | TOX2 | TOX3 | TOX4 | TP53 | TP53AIP1 | TP53BP2 | TP53I11 | TP53I13 | TP53I3 | TP53INP1 | TP53INP2 | TP53RK | TP53TG1 | TP53TG3 | TP53TG3HP | TP53TG5 | TP63 | TP73 | TP73-AS1 | TPBG | TPBGL | TPCN1 | TPCN2 | TPD52 | TPD52L1 | TPD52L2 | TPD52L3 | TPGS1 | TPGS2 | TPH1 | TPH2 | TPI1 | TPI1P1 | TPI1P2 | TPI1P3 | TPK1 | TPM1 | TPM2 | TPM3 | TPM3P5 | TPM3P7 | TPM3P9 | TPM4 | TPMT | TPO | TPP1 | TPP2 | TPPP | TPPP2 | TPPP3 | TPR | TPRA1 | TPRG1 | TPRG1-AS1 | TPRG1-AS2 | TPRG1L